MedMind Secures Tens of Millions of Yuan in Series A Funding to Advance Digital and Intelligent Oncology Solutions

VCBeat has learned that Beijing Yizhiying Technology Co., Ltd. (hereinafter referred to as “Yizhiying”) recently completed a Series A financing round worth tens of millions of yuan.This round of financing was jointly invested by Roton Capital and Lepu Medical, with Yiran Capital serving as the financial advisor in this transaction.The proceeds from this financing round will be primarily allocated to the R&D iteration and market promotion of the “RT-Solution Intelligent Integrated Radiotherapy Solution,” as well as to the iterative optimization, enhancement, and enrichment of related scientific research and regulatory registration projects.

Yizhiying, established in July 2019, is a medical AI company dedicated to developing “precision oncology treatment solutions” leveraging medical big data and artificial intelligence technologies. The company focuses on clinical target volume (CTV) delineation for oncology radiotherapy. It has completed CTV delineation solutions for breast cancer, rectal cancer, cervical cancer, lung cancer, esophageal cancer, total marrow irradiation (TMI), and pediatric tumors, as well as fully automated delineation for more than 120 organs at risk (OARs) throughout the body. Yizhiying has independently developed core products including the “Radiotherapy Contouring Delineation Software RT-Mind,” the “Intelligent Radiotherapy Workflow Management System RT-Link,” and the “Integrated Intelligent Radiotherapy Solution RT-Solution.” Building on these foundations, the company has established a portfolio of planning and navigation products covering multiple anatomical sites and diseases—such as the heart, lungs, and liver—thereby forming a comprehensive product matrix.

Adopting a strategy of “building high walls and accumulating ample reserves,” Beijing Yizhiying Technology Co., Ltd. has concentrated its efforts on the track of precision oncology treatment, engaging in intensive cultivation. The company has not only established technological barriers through innovation but also continuously expanded its product pipeline, providing the industry with numerous innovative solutions.

Currently, the company’s R&D achievements have been published in international journals such as Radiology, Medical Physics, and Radiotherapy and Oncology. Meanwhile, it has filed multiple applications for projects funded by the Ministry of Science and Technology and the National Natural Science Foundation of China. Its product, “RT-Mind Radiotherapy Contouring Software,” has obtained Class III medical device registration certification in China and market clearance from the U.S. Food and Drug Administration (FDA), with continued acceleration in market adoption.

Notably,Beijing Yizhiying Technology Co., Ltd. has pioneered the industry’s first digital and intelligent “RT-Solution Integrated Smart Radiotherapy Solution,” empowering precision oncology treatment and achieving true clinical automation in radiotherapy.

Radiotherapy is one of the most primary cancer treatment methods today.

According to data from Kaiyuan Securities, the radiotherapy market size reached RMB 51.7 billion in 2021. Driven by factors such as the increasing number of radiotherapy equipment installations, price adjustments for certain radiotherapy medical services, and the development and widespread adoption of precision radiotherapy technologies, both the penetration rate of radiotherapy and the overall market size are expected to expand further.

However, tumor radiotherapy currently faces a major pain point: the procedure is complex and highly challenging, with every stage—from initial tumor diagnosis and treatment planning to the execution of radiation therapy—heavily dependent on physicians’ expertise. In China, there are significant disparities and pronounced heterogeneity in treatment quality across hospitals. Coupled with the year-on-year rise in cancer incidence, the long training cycles for radiation oncologists and medical physicists have resulted in a persistent shortage of experienced professionals in small and medium-sized hospitals, making it difficult to improve the overall efficacy of radiotherapy.

Dr. Wang Shaobin, founder of Yizhiying Technology and a veteran with 17 years of deep expertise in the healthcare industry, is among the earliest scientists in China to conduct research in artificial intelligence. He has held key positions at medical technology companies such as Canon Medical Systems and Toshiba Medical Systems, where he led teams to successfully develop multiple clinically applied products and secured over ten global patents. Dr. Wang told VCBeat: “Clinical target volume delineation is critical to radiotherapy, determining 60% of its efficacy. On one hand, there is significant variability in target delineation across different centers and among different physicians. On the other hand, the process is time-consuming, labor-intensive, and repetitive. Achieving a technological breakthrough in this area is essential for quality control at the source, thereby enabling truly homogeneous treatment across hospitals of all sizes within individual institutions, regions, and throughout China.”

It is precisely based on this understanding thatYizhiying has chosen "fully automated delineation of Clinical Target Volume (CTV) for oncology"—the most technically challenging yet clinically valuable application—as its breakthrough point since its inception.

Leveraging over a decade of accumulated expertise in image processing and artificial intelligence, Yizhiying has successfully transformed the therapeutic experience of oncologists and medical physicists into deep learning models and products. Through its intelligent Dr. Twin® system, the company replicates top-tier hospital diagnostics and treatment protocols across healthcare institutions at all levels, providing homogeneous, tireless “Twin Doctor” intelligent radiotherapy solutions that empower the automation and intelligent optimization of complex cancer treatment workflows.

The company’s flagship product, “RT-Mind Intelligent Target Delineation,” is built on a foundation of over 60,000 high-quality training samples. It not only covers major cancer types throughout the body but also leverages key technologies to achieve automatic delineation of clinical target volumes (CTV). Reportedly, the system boasts an accuracy rate exceeding 95%, with a delineation speed of under 10 seconds. It is fully compatible with mainstream radiotherapy systems and has demonstrated a 100-fold improvement in efficiency, as validated by multi-center clinical trials.

Now, the company has taken a further step by launching the “RT-Solution Intelligent Integrated Radiotherapy Solution.”This solution aims to automate radiotherapy by leveraging a product suite that includes RT-Mind for automatic target delineation, RT-Link for intelligent workflow management, RT-AutoPlan for intelligent automated planning, RT-Veri for intelligent dose verification, and ART-Mind for adaptive radiotherapy, thereby empowering the development of new radiotherapy infrastructure.

Moreover, RT-Solution is equipped with the RT-DMS, a comprehensive big data management platform, and supported by the RT-Cloud remote radiotherapy collaboration platform. This integrated system delivers precise treatment services to patients, provides reliable intelligent assistance tools for physicians and medical physicists, and enhances the operational efficiency and informatization level of hospitals and departments.

Looking back on Yizhiying’s journey, the company has remained steadfastly focused on developing “precision oncology treatment solutions” since its inception. By collaborating with Tsinghua University and leading experts from top-tier hospitals across China—including Peking Union Medical College Hospital, Peking University Cancer Hospital, and Henan Cancer Hospital—the company continuously iterates and optimizes its technologies. It provides a flexible portfolio of products adapted to existing clinical workflows, including fully automated contouring tools, feature-rich radiotherapy workstations, and cloud-based remote radiotherapy systems. These innovations truly empower the entire radiotherapy process with AI, enhancing the efficiency of radiation oncologists and medical physicists.

In the future, Yizhiying will also accelerate product launches and expand its overseas presence. Meanwhile, it will work closely with the Radiation Oncology Branch of the Chinese Medical Association, the Chinese Association of Medical Equipment, and the Chinese Society of Nuclear Medicine to develop regional healthcare networks, enhance treatment capabilities at the county level, and facilitate the decentralization of medical resources.

Roton Capital stated“The Yizhiying team hails from Toshiba Medical, a Fortune Global 500 company and a leading global supplier of medical imaging solutions. Moreover, the Yizhiying team has established advanced image processing technologies and algorithmic models, and has formed strategic collaborations with top-tier hospitals such as Peking Union Medical College Hospital and Peking University Cancer Hospital. The company’s independently developed products have received approval for market launch from China’s National Medical Products Administration (NMPA) and the U.S. FDA via the 510(k) clearance pathway, earning high recognition from experts at leading hospitals. After two years of development, the company has built a diversified product portfolio and achieved initial commercialization. We are confident that Yizhiying will continue to introduce more valuable ‘Precision Oncology Treatment Solutions,’ thereby contributing to the growth of the oncology healthcare services market!”

Lepu Medical stated: “The core team of Yizhiying Technology hails from internationally renowned medical device companies. With over a decade of deep expertise in medical device hardware and software, artificial intelligence, big data, and clinical applications, the team combines a global perspective with strong local execution capabilities. It is a rare multidisciplinary team proficient in technology, industry insights, market dynamics, and clinical practice. The tumor treatment market exceeds RMB 300 billion, with the radiotherapy segment accounting for RMB 50 billion. However, precision therapy demands higher and more stringent technical and product standards. Currently, digital and intelligent therapies are in a stage of vigorous development, offering substantial growth potential. Although Yizhiying Technology was established relatively recently, it has developed a comprehensive portfolio of precision oncology products, obtained NMPA Class III medical device registration certificates and FDA clearance, achieved installations in over 250 hospitals worldwide, and gained high recognition from experts both domestically and internationally, demonstrating significant development potential and competitive advantages.”

Yiran Capital stated“Yiran Capital is highly optimistic about the application of AI in the field of radiation therapy. This sector represents a market with ‘inelastic demand and strong payment capacity,’ a characteristic that ensures robust implementation and monetization capabilities for the industry. The team at Yizhiying is not only deeply rooted in this field, but its members also hail from leading global medical imaging enterprises. Currently, the company’s products have gained recognition and endorsement from senior experts in the industry, with rapid growth in installation volume. We look forward to the company’s continued commercial expansion and sustained industry leadership, driven by the synergy of ‘industrial resources and capital resources.’”

Roton Capital focuses on private equity investment, guided by the core principles of “integrity, professionalism, collaboration, and innovation,” driven by the mission to “enhance resource allocation efficiency,” with primary investment sectors in healthcare, clean energy, and advanced manufacturing.

Lepu Medical Technology (Beijing) Co., Ltd. (“Lepu Medical”, stock code: 300003) was founded in 1999. It is one of the earliest enterprises in China engaged in the research, development, and manufacturing of cardiovascular interventional medical devices, and among the few domestic companies capable of competing strongly with foreign products in the high-end medical device sector. In the future, the company will continue to improve its full-lifecycle industrial platform covering the prevention, diagnosis, treatment, and rehabilitation of cardiovascular diseases, striving to build a specialized ecosystem featuring “Cardiovascular Health + Anti-Tumor” solutions, so as to provide advanced products and high-quality services to more patients with cardiovascular and oncological diseases.

Yiran Capital was established in 2020. With a professional background from Peking University Healthcare, the team is dedicated to providing comprehensive and in-depth financing services to high-quality healthcare enterprises in the fields of innovative drugs, medical devices (IVD), and healthcare services. The firm accurately grasps industry trends and possesses extensive experience in project capital operations.